ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 187,63
0,28%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alpine Immune Sciences Inc (ALPN)

  7. Alpine Immune Sciences Inc (ALPN) Actualités

ALPN Alpine Immune Sciences Inc

64,97
0,00 (0,00%)
14 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Alpine Immune Sciences Inc ALPN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 64,97 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
64,97 64,97
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/5/202415:12EDGAR2Form 15-12G - Securities registration termination [Section..
24/5/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
21/5/202422:49EDGAR2Form SC 13D/A - General statement of acquisition of..
21/5/202416:21EDGAR2Form SC 13D/A - General statement of acquisition of..
21/5/202402:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202402:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202402:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202402:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202402:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202414:53EDGAR2Form S-8 POS - Securities to be offered to employees in..
20/5/202414:42EDGAR2Form POS AM - Post-Effective amendments for registration..
20/5/202414:38EDGAR2Form 8-K - Current report
20/5/202414:27EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
11/5/202401:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/5/202401:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/5/202401:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/5/202414:30EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
09/5/202422:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:09EDGAR2Form 8-K - Current report
09/5/202422:00BWAlpine Immune Sciences Reports First Quarter 2024 Financial..
07/5/202414:30EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
11/4/202422:27PRNUSKuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to..
11/4/202413:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
10/4/202422:15BWAlpine Immune Sciences Shares Updated Clinical Data from..
10/4/202422:01BWVertex Enters Into Agreement to Acquire Alpine Immune..
01/4/202415:00BWAlpine Immune Sciences to Present Updated Clinical Data for..
21/3/202412:45BWAlpine Immune Sciences Presents New Translational Data on..
20/3/202421:30BWAlpine Immune Sciences to Participate in Upcoming H.C...
18/3/202421:05BWAlpine Immune Sciences Provides Corporate Update and Full..
07/3/202422:30BWAlpine Immune Sciences to Report Fourth Quarter and Full..
26/2/202422:30BWAlpine Immune Sciences to Participate in Two Upcoming..
14/2/202422:43EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202415:22EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202422:12EDGAR2Form 8-K - Current report
01/2/202422:30BWAlpine Immune Sciences to Participate in Two Upcoming..
23/1/202400:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202400:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/1/202400:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:45EDGAR2Form 8-K - Current report
05/1/202401:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202322:23EDGAR2Form 8-K - Current report
21/12/202322:15BWAlpine Immune Sciences Announces Amendment of Acazicolcept..
18/12/202322:30BWAlpine Immune Sciences to Present at the 42nd Annual J.P...
22/11/202316:25EDGAR2Form SC 13D/A - General statement of acquisition of..
20/11/202322:30BWAlpine Immune Sciences to Participate in the Evercore ISI..
15/11/202315:00BWAlpine Immune Sciences Presents New Translational Data on..
14/11/202322:15BWAlpine Immune Sciences Reports Third Quarter 2023 Financial..
13/11/202315:00BWAlpine Immune Sciences Presents New Translational Data on..
07/11/202303:41BWAlpine Immune Sciences Announces Pricing of $150 Million..

Dernières Valeurs Consultées

NASDAQ
ALPN
Alpine Immune Sciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés